Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. METHODS: In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium-223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium-223. RESULTS: At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The updated analysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. CONCLUSIONS: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“R adiopharmaceutical therapies are gaining increasing prominence as they improve survival in patients with common diseases such as metastatic prostate cancer ( 1 , 2 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [2]
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“These are particularly substantial in the post-ARPI space, as pivotal trials of many current treatments were performed in patients who had not received a prior ARPI [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Additionally, pivotal trials of current treatments utilized conventional imaging to determine metastatic disease [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Best standard non- | ALSYMPCA Castration refractory | OS | | | 11.3 months 3.6 months | 0.70 (0.55-0.88) Improved | 5 | [68]”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“Asthenia 35 (6) 5 (1) 0 0 18 (6) 4 (1) 0 0”
InfluentialSelf-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Research works printed but not linked: 4
- Lewington VJ, 2005, J Nucl Med, 46, 38S
- Henriksen G, 2002, Cancer Res, 62, 3120
- Henriksen G, 2003, J Nucl Med, 44, 252
- Liepe K, 2009, Curr Opin Investig Drugs, 10, 1346
Cited by
Items 401–500 of 1,005
Gafita, A., Fendler, W. P., Hui, W., Sandhu, S., Weber, M., Esfandiari, R., Calais, J., Rauscher, I., Rathke, H., Tauber, R., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.05.004 · Cited by 61
Kim, T. J., & Koo, K. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155484 · Cited by 73
PSMA Theranostics: Current Landscape and Future Outlook
Zhang, H., Koumna, S., Pouliot, F., Beauregard, J., & Kolinsky, M. P. (2021) · Cancers · doi:10.3390/cancers13164023 · Cited by 69
“Systemic radiation with alpha particle-emitting calcium mimetic Radium-223 (223Ra) has been established for metastatic prostate cancer localized to the bone [27].”
BackgroundInfluentialDevelopment of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
Pallares, R. M., & Abergel, R. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1020188 · Cited by 75
“Although β-emitters, such as 89Sr and 153Sm, only provide pain palliation in bone-metastatic prostate cancer patients (21, 22), 223Ra yields both survival benefits as well as pain reduction when added to best standard of care (23, 24).”
Backgroundvan Soest, R. J., Nieuweboer, A. J. M., de Morrée, E. S., Chitu, D. A., Bergman, A. M., Goey, S. H., Bos, M. M. E. M., van der Meer, N., Hamberg, P., de Wit, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.037 · Cited by 64
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer
McDevitt, M. R., Thorek, D. L. J., Hashimoto, T., Gondo, T., Veach, D. R., Sharma, S. K., Kalidindi, T. M., Abou, D. S., Watson, P. A., Beattie, B. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04107-w · Cited by 59
Kulkarni, H., Singh, A., Langbein, T., Schuchardt, C., Müeller, D., Zhang, J., Lehmann, C., & Baum, R. P. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180308 · Cited by 65
Pisano, C., Tucci, M., Stefano, R. F. D., Turco, F., Scagliotti, G. V., Maïo, M. D., & Buttigliero, C. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103185 · Cited by 63
Passildas, J., Eymard, J., Pouget, M., Kwiatkowski, F., Praagh, I. V., Savareux, L., Atger, M., Durando, X., Abrial, C., Richard, D., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3806 · Cited by 67
Rosar, F., Krause, J., Bartholomä, M. D., Maus, S., Stemler, T., Hierlmeier, I., Linxweiler, J., Ezziddin, S., & Khreish, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050722 · Cited by 62
“In the stage of mCRPC, taxane-based chemotherapy (docetaxel and cabazitaxel) [6,7], treatment with novel androgen axis drugs (NAAD) (abiraterone or enzalutamide) [8,9] and bone-seeking 223Ra therapy (Xofigo®) [10] are currently the standard treatment options [11], which are approved by the European Medicines Agency (E…”
BackgroundRadium-223 in the Treatment of Osteoblastic Metastases: A Critical Clinical Review
Humm, J. L., Sartor, O. A., Parker, C. C., Bruland, Ø. S., & Macklis, R. M. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.12.061 · Cited by 61
Self-citationLord, J., Willis, S., Eatock, J., Tappenden, P., Trapero‐Bertran, M., Miners, A. H., Crossan, C., Westby, M. J., Anagnostou, A., Taylor, S. J. E., et al. (2013) · Health Technology Assessment · doi:10.3310/hta17580 · Cited by 70
Recent advances in bone-targeted therapies of metastatic prostate cancer
Deng, X., He, G., Liu, J., Luo, F., Peng, X., Tang, S., Gao, Z., Lin, Q., Keller, J. M., Yang, T., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.04.003 · Cited by 60
Flaig, T. W., Potluri, R. C., Ng, Y., Todd, M. B., & Mehra, M. (2015) · Cancer Medicine · doi:10.1002/cam4.576 · Cited by 65
Galeterone for the treatment of advanced prostate cancer: the evidence to date
Antonarakis, E. S., & Bastos, D. A. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s93941 · Cited by 66
Lohiya, V., Aragon-Ching, J. B., & Sonpavde, G. (2016) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s34535 · Cited by 60
DNA vaccines for prostate cancer
Zahm, C. D., Colluru, V. T., & McNeel, D. G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.016 · Cited by 64
“, 2012), bone-targeted radiation therapy with radium-223 (Parker et al., 2013), and an autologous cellular vaccine sipuleucel-T (Kantoff et al.”
BackgroundDisparities in prostate cancer incidence and mortality rates: Solvable or not?
Badal, S. A. M., Aiken, W. D., Morrison, B. F., Valentine, H., Bryan, S., Gachii, A., & Ragin, C. C. R. (2019) · The Prostate · doi:10.1002/pros.23923 · Cited by 74
“Radium‐ 223 dichloride emits alpha particles which binds to areas of metastases in bone and is cytotoxic in these areas.(168) Recent advances in drug treatment seek to discover new agents”
Cyclotron production of 225Ac from an electroplated 226Ra target
Nagatsu, K., Suzuki, H., 深田, 正., Ito, T., Ichinose, J., Honda, Y., Minegishi, K., Higashi, T., & Zhang, M. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05460-7 · Cited by 70
The coordination properties and ionic radius of actinium: A 120-year-old enigma
Deblonde, G. J. ‐., Zavarin, M., & Kersting, A. B. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214130 · Cited by 64
Izzo, D., Ascione, L., Guidi, L., Marsicano, R. M., Koukoutzeli, C., Trapani, D., & Curigliano, G. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241309461 · Cited by 67
Bæksted, C., Pappot, H., Nissen, A., Hjøllund, N. H., Mitchell, S. A., Basch, E., Bidstrup, P. E., Dalton, S. O., & Johansen, C. (2017) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-017-0005-6 · Cited by 63
“Items from PRO-CTCAE corresponding to the symptomatic adverse-events profile associated with systemic treatment of prostate cancer using Docetaxel, Cabazi-taxel, Abiraterone or Alpharadin in phase III clinical, randomized trials were used in this study [17 – 20].”
MethodRathkopf, D. E., Beer, T. M., Loriot, Y., Higano, C. S., Armstrong, A. J., Sternberg, C. N., Bono, J. S. D., TOMBAL, B. F., Parli, T., Bhattacharya, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5808 · Cited by 67
Maffey-Steffan, J., Scarpa, L., Svirydenka, A., Nilica, B., Mair, C., Buxbaum, S., Bektić, J., von Guggenberg, E., Uprimny, C., Horninger, W., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04583-2 · Cited by 62
Fong, L. H., Morris, M. J., Sartor, O. A., Higano, C. S., Pagliaro, L. C., Alva, A. S., Appleman, L. J., Tan, W. W., Vaishampayan, U. N., Porcu, R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0063 · Cited by 63
“Radium-223 dichloride (radium-223) has been approved for the treatment of patients with CRPC and symptomatic bone metastases but without known visceral metastatic disease (19, 20).”
BackgroundSelf-citationMolecular landscape of prostate cancer: Implications for current clinical trials
Khemlina, G., Ikeda, S., & Kurzrock, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.07.001 · Cited by 65
Lange, R., ter Heine, R., Knapp, R., de Klerk, J. M. H., Bloemendal, H. J., & Hendrikse, N. H. (2016) · Bone · doi:10.1016/j.bone.2016.08.002 · Cited by 59
miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression
Chakravarthi, B. V. S. K., Chandrashekar, D. S., Agarwal, S., Balasubramanya, S. A. H., Pathi, S. S., Goswami, M. T., Jing, X., Wang, R., Mehra, R., Asangani, I. A., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0230 · Cited by 59
Fan, L., Wang, R., Chi, C., Cai, W., Zhang, Y., Qian, H., Shao, X., Wang, Y., Xu, F., Pan, J., et al. (2017) · The Prostate · doi:10.1002/pros.23465 · Cited by 67
Wargowski, E., Johnson, L. E., Eickhoff, J. C., Delmastro, L., Staab, M. J., Liu, G., & McNeel, D. G. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0333-y · Cited by 59
“including docetaxel [2, 3], cabazitaxel [4], abiraterone [5], radium-223 [6], and enzalutamide [7].”
BackgroundParikh, S. A., Murray, L. J., Kenning, L., Bottomley, D., Din, O. S., Dixit, S., Ferguson, C., Handforth, C., Joseph, L. A., Mokhtar, D., et al. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.06.004 · Cited by 59
Self-citationBasch, E., Scholz, M. C., Bono, J. S. D., Vogelzang, N. J., SOUZA, P. D., Marx, G. M., Vaishampayan, U. N., George, S., Schwarz, J. K., Antonarakis, E. S., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.11.033 · Cited by 66
Self-citationAhmadzadehfar, H., Azgomi, K., Hauser, S., Wei, X. X., Yordanova, A., Gaertner, F. C., Kürpig, S., Strunk, H. M., & Essler, M. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178533 · Cited by 59
“Therefore, it is recommended that patients receive all 6 cycles of 223Ra, which is the recommended treatment course to achieve an overall survival benefit (13,14).”
Backgroundvan der Doelen, M. J., Velho, P. I., Slootbeek, P. H. J., Naga, S. P., Bormann, M., van Helvert, S., Kroeze, L. I., van Oort, I. M., Gerritsen, W. R., Antonarakis, E. S., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.05.001 · Cited by 59
Schaefer-Schuler, A., Burgard, C., Blickle, A., Maus, S., Petrescu, C., Petto, S., Bartholomä, M. D., Stemler, T., Ezziddin, S., & Rosar, F. (2024) · Theranostics · doi:10.7150/thno.92273 · Cited by 66
“Common treatments for mCRPC patients include new androgen axis drugs as abiraterone or enzalutamide [4,5], chemotherapy with docetaxel or cabazitaxel [6,7], bone seeking radiation therapy with Ra-223 [8], and PARP inhibitors as e.g. Olaparib [9].”
Oudard, S. M., Kramer, G., Caffo, O., Creppy, L., Loriot, Y., Hansen, S., Holmberg, M., Rolland, F., Machiels, J., & Krainer, M. (2014) · British Journal of Urology · doi:10.1111/bju.12845 · Cited by 66
Xie, W., Regan, M. M., Buyse, M. E., Halabi, S., Kantoff, P. W., Sartor, O. A., Soule, H. R., Berry, D. A., Clarke, N. W., Collette, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03114 · Cited by 63
“© 2020 by American Society of Clinical Oncology INTRODUCTION Despite various strategies for the early detection of prostate cancer, more than one half of all deaths occur in men who initially presented with localized disease.1 Curing metastatic prostate cancer is still a formidable challenge, and the most likely near-…”
BackgroundInfluentialSelf-citationProstate Cancer in the Elderly Patient
Fung, C., Dale, W., & Mohile, S. G. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1531 · Cited by 60
Rosar, F., Dewes, S., Ries, M., Schaefer, A., Khreish, F., Maus, S., Bohnenberger, H., Linxweiler, J., Bartholomä, M. D., Ohlmann, C., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04674-0 · Cited by 60
203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer
Li, M., Sagastume, E. A., Lee, D., McAlister, D. R., DeGraffenreid, A. J., Olewine, K. R., Graves, S. A., Copping, R., Mirzadeh, S., Zimmerman, B. E., et al. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200727190423 · Cited by 64
Factors affecting 223Ra therapy: clinical experience after 532 cycles from a single institution
Etchebehere, E., Milton, D. R., Araujo, J. C., Swanston, N. M., Macapinlac, H. A., & ROHREN, E. M. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3185-4 · Cited by 57
Bone remodeling markers and bone metastases: From cancer research to clinical implications
Ferreira, A. R., Alho, I., Casimiro, S., & Costa, L. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.35 · Cited by 62
Nonnekens, J., Chatalic, K. L. S., Molkenboer‐Kuenen, J. D. M., Beerens, C. E. M. T., Bruchertseifer, F., Morgenstern, A., Veldhoven-Zweistra, J., Schottelius, M., Wester, H., van Gent, D. C., et al. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2016.2155 · Cited by 70
Morris, M. J., Loriot, Y., Sweeney, C. J., Fizazi, K. S., Ryan, C. J., Shevrin, D. H., Antonarakis, E. S., Pandit-Taskar, N. D., Deandreis, D., Jacene, H. A., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.007 · Cited by 59
“Clinically, radium-223—given at a dose of 55 kBq/kg every 4 weeks for 6 doses—prolongs life and the time to first symptomatic skeletal event in patients with bone-predominant metastatic castration-resistant prostate cancer (mCRPC) and no known visceral metastases [5].”
BackgroundCytoreductive treatment strategies for de novo metastatic prostate cancer
Connor, M. J., Shah, T. T., Horan, G., Bevan, C. L., Winkler, M. H., & Ahmed, H. U. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0284-3 · Cited by 59
Disparities in Castration-Resistant Prostate Cancer Trials
Spratt, D. E., & Osborne, J. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1751 · Cited by 59
Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
Kuo, P. H., Benson, T., Messmann, R., & Groaning, M. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263638 · Cited by 56
“The ALSYMPCA trial with (223)Ra-chloride included patients with lymphadenopathy up to 3 cm in short-axis diameter and showed that benefit in overall survival could be achieved in patients with bone metastases without treating nodes up to 3 cm (9).”
MethodLejeune, P., Cruciani, V., Berg‐Larsen, A., Schlicker, A., Mobergslien, A., Bartnitzky, L., Berndt, S., Zitzmann-Kolbe, S., Kamfenkel, C., Stargard, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002387 · Cited by 62
“12 Similarly, Malamas et al. 13 demonstrated that in vitro exposure of prostate, lung, and breast cancer cells to the TAT radium-223 dichloride 14 resulted in the exposure of DAMPs and MHC-1 on the cell surface, rendering cells vulnerable to T cell-mediated cell lysis.”
Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications
Baldessari, C., Pipitone, S., Molinaro, E., Cerma, K., Fanelli, M., Nasso, C., Oltrecolli, M., Pirola, M., D’Agostino, E., Pugliese, G., et al. (2023) · Cancers · doi:10.3390/cancers15051518 · Cited by 74
“Radium-223-dichloride binds with high-affinity hydroxyapatite in sites with elevated bone turnover, and has a local cytotoxic effect via double-strand DNA breaks [114].”
BackgroundInfluentialAdvances in the treatment of metastatic prostate cancer
Gebrael, G., Fortuna, G. G., Sayegh, N., Swami, U., & Agarwal, N. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.06.009 · Cited by 59
The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer
Heidegger, I. M., Massoner, P., Sampson, N., & Klocker, H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.026 · Cited by 61
Cannistraci, A., Pace, A. L. D., Maria, R. D., & Bonci, D. (2014) · BioMed Research International · doi:10.1155/2014/146170 · Cited by 60
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
Stein, M., Patel, N., Bershadskiy, A., Sokoloff, A., & Singer, E. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.129133 · Cited by 67
Androgen deprivation therapy as backbone therapy in the management of prostate cancer
Merseburger, A. S., Alcaraz, A., & von Klot, C. A. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s117176 · Cited by 62
Kalina, J. L., Neilson, D. S., Comber, A. P., Rauw, J. M., Alexander, A., Vergidis, J., & Lum, J. J. (2017) · Cancers · doi:10.3390/cancers9020013 · Cited by 58
“The pivotal Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial demonstrated improvements in overall survival, freedom from symptomatic skeletal events, pain control, and quality of life for radium-223 over placebo [40].”
BackgroundCirculating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer
Sonpavde, G., Agarwal, N., Pond, G. R., Nagy, R. J., Nussenzveig, R. H., Hahn, A. W., Sartor, O. A., Gourdin, T. S., Nandagopal, L., Ledet, E. M., et al. (2019) · Cancer · doi:10.1002/cncr.31959 · Cited by 57
Self-citationFactors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
Caram, M. E. V., Ross, R. D., Lin, P., & Mukherjee, B. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2589 · Cited by 62
O’Steen, S., Comstock, M., Orozco, J. J., Hamlin, D. K., Wilbur, D. S., Jones, J. C., Kenoyer, A. L., Nartea, M. E., Lin, Y., Miller, B. W., et al. (2019) · Blood · doi:10.1182/blood.2019001250 · Cited by 61
Hagemann, U. B., Wickstroem, K., Hammer, S., Bjerke, R. M., Zitzmann-Kolbe, S., Ryan, O. B., Karlsson, J., Scholz, A., Hennekes, H., Mumberg, D., et al. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3568 · Cited by 58
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
Bidkar, A. P., Wang, S., Bobba, K. N., Chan, E., Bidlingmaier, S. M., Egusa, E. A., Peter, R., Ali, U., Meher, N., Wadhwa, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3291 · Cited by 66
“Therapeutic options for patients with mCRPC include androgen signaling inhibitors, chemotherapy, immunotherapy, and radiopharmaceutical therapies including (177)Lu-PSMA-617 (Lu-177 vipivotide tetraxetan) or (223)Ra (2, 3).”
BackgroundArmstrong, A. J., Häggman, M., Stadler, W. M., Gingrich, J. R., Assikis, V. J., Polikoff, J. A., Damber, J. ‐., Belkoff, L. H., Nordle, Ö., Forsberg, G., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1581 · Cited by 57
Functional screen identifies kinases driving prostate cancer visceral and bone metastasis
Faltermeier, C. M., Drake, J. M., Clark, P. M., Smith, B. A., Zong, Y., Volpe, C., Mathis, C., Morrissey, C. M., Castor, B., Huang, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521674112 · Cited by 60
James, N. D., Pirrie, S. J., Pope, A., Barton, D., Andronis, L., Goranitis, I., Collins, S. I., McLaren, D. B., O’Sullivan, J. M., Parker, C. C., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20530 · Cited by 57
Self-citationParker, C. C., Zhan, L., Cislo, P. R., Reuning-Scherer, J. D., Vogelzang, N. J., Nilsson, S. F., Sartor, O. A., O’Sullivan, J. M., & Coleman, R. E. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.020 · Cited by 55
Self-citationDu, Y., Carrió, I., VINCENTIS, G. D., Fanti, S., Ilhan, H., Mommsen, C., Nitzsche, E. U., Sundram, F., Vogel, W. V., Oyen, W. J. G., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3756-7 · Cited by 63
“In the Phase 3 ALSYMPCA study among patients with CRPC and symptomatic bone metastases, radium-223 significantly improved overall survival (primary endpoint) and median time to first symptomatic skeletal-related event (both p < 0.001; Table 1), compared with placebo, and had a favourable safety profile [3].”
InfluentialMolecular alterations and emerging targets in castration resistant prostate cancer
Lorente, D., & Bono, J. S. D. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.12.004 · Cited by 60
He, L., Fang, H., Chen, C., Wu, Y., Wang, Y., Ge, H., Wang, L., Wan, Y., & He, H. (2020) · Medicine · doi:10.1097/md.0000000000019760 · Cited by 58
Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
Perera, O. M., Thomas, P. B., Risbridger, G. P., Taylor, R. A., Azad, A., Hofman, M. S., Williams, E. D., & Vela, I. (2022) · Cancers · doi:10.3390/cancers14030503 · Cited by 55
“6 months versus the placebo in men with mCRPC [21].”
BackgroundTOMBAL, B. F., Choudhury, A., Saad, F., Gallardo, E., Soares, A., Loriot, Y., McDermott, R., Rodriguez-Vida, A., Velho, P. I., Nolè, F., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.011 · Cited by 69
Radionanomedicine: Widened perspectives of molecular theragnosis
Lee, D. S., Im, H., & Lee, Y. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.12.010 · Cited by 61
Shigeta, K., Kosaka, T., Kitano, S., Yasumizu, Y., Miyazaki, Y. J., Mizuno, R., Shinojima, T., Kikuchi, E., Miyajima, A., Tanoguchi, H., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5354-5 · Cited by 59
SEOM Clinical Guideline for bone metastases from solid tumours (2016)
Grávalos, C., Rodriguez, C. A., Sabino, A., Seguí, M. Á., Virizuela, J. A., Carmona‐Bayonas, A., Cassinello, J., Isla, D., Jara, C., & Martín, M. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1590-1 · Cited by 62
Fankhauser, C. D., Schüffler, P. J., Gillessen, S., Omlin, A. G., Rupp, N. J., Rueschoff, J. H., Hermanns, T., Poyet, C., Sulser, T., Moch, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22888 · Cited by 56
“Recent clinical trials have led to the FDA approval of cabazitaxel [1], abiraterone [2–4], enzalutamide [5, 6], radium-223 [7], and Sipuleucel-T [8].”
Den, R. B., George, D. J., Pieczonka, C. M., & McNamara, M. A. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000528 · Cited by 63
Diseases of the Abdomen and Pelvis 2018-2021
Hodler, J., Huch, R., & von Schulthess, G. K. (2018) · IDKD Springer series · doi:10.1007/978-3-319-75019-4 · Cited by 60
Trial Watch: Radioimmunotherapy for oncological indications
Bloy, N., Pol, J. G., Manic, G., Vitale, I., Eggermont, A. M. M., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954929 · Cited by 56
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy
Omlin, A. G., Pezaro, C., & Gillessen, S. (2013) · Therapeutic Advances in Urology · doi:10.1177/1756287213509677 · Cited by 58
Xu, N., Wu, Y., Yin, H., Xue, X., & Gou, X. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1637-x · Cited by 75
Exploiting bone niches: progression of disseminated tumor cells to metastasis
Muscarella, A. M., Aguirre, S., Hao, X., Waldvogel, S. M., & Zhang, X. H.-F. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143764 · Cited by 59
McNeel, D. G., Eickhoff, J. C., Wargowski, E., Johnson, L. E., Kyriakopoulos, C. E., Emamekhoo, H., Lang, J. M., Brennan, M. J., & Liu, G. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004198 · Cited by 54
Advances and challenges in precision imaging
Hricak, H., Mayerhoefer, M. E., Herrmann, K., Lewis, J. S., Pomper, M. G., Hess, C. P., Riklund, K., Scott, A. M., & Weissleder, R. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00395-4 · Cited by 63
Izumi, K., Ikeda, H., Maolake, A., Machioka, K., Nohara, T., Narimoto, K., Ueno, S., Kadono, Y., Kitagawa, Y., Konaka, H., et al. (2015) · The Prostate · doi:10.1002/pros.22985 · Cited by 57
Howard, L. E., Hoedt, A. M. D., Aronson, W. J., Kane, C. J., Amling, C. L., Cooperberg, M. R., Terris, M. K., Divers, C., Valderrama, A., & Freedland, S. J. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.26 · Cited by 53
Pérez-López, R., Rodrigues, D. N., Figueiredo, I., Mateo, J., Collins, D. J., Koh, D., Bono, J. S. D., & Tunariu, N. (2017) · Investigative Radiology · doi:10.1097/rli.0000000000000415 · Cited by 58
Ahmadzadehfar, H., Rahbar, K., Essler, M., & Biersack, H. J. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.07.003 · Cited by 55
Clinical utility of emerging biomarkers in prostate cancer liquid biopsies
Boerrigter, E., Groen, L., van Erp, N. P., Verhaegh, G. W. C. T., & Schalken, J. A. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1675515 · Cited by 59
Prostate Cancer Immunotherapy—Finally in From the Cold?
Runcie, K. D., & Dallos, M. C. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01084-0 · Cited by 54
Radiometabolic Treatment of Bone-Metastasizing Cancer: From 186 Rhenium to 223 Radium
Rubini, G., Nicoletti, A., Rubini, D., & Asabella, A. N. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2013.1549 · Cited by 58
Shore, N. D. (2015) · Urology · doi:10.1016/j.urology.2014.11.031 · Cited by 56
Hagemann, U. B., Mihaylova, D., Uran, S. R., Borrebaek, J., Grant, D., Bjerke, R. M., Karlsson, J., & Cuthbertson, A. (2017) · Oncotarget · doi:10.18632/oncotarget.16910 · Cited by 52
“The recent approval of the first-in-class alpha radiopharmaceutical Xofigo (radium-223 dichloride, (223)RaCl2) for the treatment of metastatic castration resistant prostate cancer [3] by the Food and Drug Administration (FDA) has further increased the interest in new applications of TAT.”
BackgroundSuzuki, H. Y., Kaizuka, Y., Tatsuta, M., TANAKA, H. L., Washiya, N., Shirakami, Y., Ooe, K., Toyoshima, A., Watabe, T., Teramoto, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01147 · Cited by 52
Coleman, R. E., Brown, J. E., & Holen, I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00056-6 · Cited by 73
Self-citationChromatin and the Cellular Response to Particle Radiation-Induced Oxidative and Clustered DNA Damage
Danforth, J. M., Provencher, L., & Goodarzi, A. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.910440 · Cited by 57
“…| Volume 10 | Article 91044015 exposure as a terrestrial environmental hazard, cosmic radiation, as well as in cancer treatment (Darby et al., 2005; Krewski et al., 2005; Cucinotta et al., 2006; Mohamad et al., 2017; Gaskin et al., 2018; Nelson, Andersson, and Wuest 2021; Pearson et al., 2021).”
BackgroundPatell, K., Kurian, M., Garcia, J. A., Mendiratta, P., Barata, P. C., Jia, A. Y., Spratt, D. E., & Brown, J. R. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2213892 · Cited by 62
“[11], enzalutamide (2012) [12], alpha-emitter radium-223 (2013) [13], rucaparib (2020) [14], and olaparib (2020) [15] for mCRPC [16].”
Targeted α-Particle Therapy of Bone Metastases in Prostate Cancer
Jadvar, H., & Quinn, D. I. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000290 · Cited by 57
Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
Graham, L. S., & Schweizer, M. T. (2016) · Medical Oncology · doi:10.1007/s12032-016-0759-3 · Cited by 56
Anderson, P. M., Subbiah, V., & ROHREN, E. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_16 · Cited by 58
Loriot, Y., Fizazi, K. S., Bono, J. S. D., Forer, D., Hirmand, M., & Scher, H. I. (2016) · Cancer · doi:10.1002/cncr.30336 · Cited by 55
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes
Claps, M., Mennitto, A., Guadalupi, V., Sepe, P., Stellato, M., Zattarin, E., Gillessen, S., Sternberg, C. N., Berruti, A., de Braud, F., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102057 · Cited by 54
Zukotynski, K., Jadvar, H., Capala, J., & Fahey, F. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s31804 · Cited by 51
Metadata
- Authors
- Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottomley, D., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall'Oglio, M., Franzén, L., Coleman, R., Vogelzang, N. J., O'Bryan-Tear, C. G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, Ø. S., & Sartor, O.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 213-223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141454098
- Cited by
- 3,408
- References
- 36
- Citations by year
- 2026: 162 · 2025: 213 · 2024: 230 · 2023: 252 · 2022: 253 · 2021: 307 · 2020: 274 · 2019: 268 · 2018: 321 · 2017: 279 · 2016: 288 · 2015: 253 · 2014: 250 · 2013: 50
- FWCI
- 228.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- radium-223 dichloride, alpha-emitting radiopharmaceuticals, castration-resistant prostate cancer, bone metastasis, overall survival, skeletal-related events, docetaxel, myelosuppression, treatment safety, ALSYMPCA trial, interim analysis
- MeSH terms
- Aged, Aged, 80 and over, Bone Neoplasms, Double-Blind Method, Humans, Isotopes, Male, Middle Aged, Prostatic Neoplasms, Radium, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.